Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
The discussants envisioned the future Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) landscape. Dr Jabbour foresees identifying patients still needing intensive therapy, better tyrosine kinase inhibitors, preventing central nervous system relapse, and potentially stopping therapy after several years via measurable residual disease monitoring. Chemo-free approaches are imminent. Dr McCloskey concurred, highlighting community implementation challenges but tremendous improvements for quality of life. Dr Abbas contrasted historic posttransplant outcomes with far superior responses from today’s oral targeted therapy. Further optimizing initial Ph+ ALL treatment stands to enrich more patient lives. Ongoing advances promise even brighter futures.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CAR T Proves Effective and Safe for Refractory Multiple Myeloma
May 15th 2024Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.
Read More
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More